Double-Edged Role of Statins in Angiogenesis Signaling
Top Cited Papers
- 5 April 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 90 (6) , 737-744
- https://doi.org/10.1161/01.res.0000014081.30867.f8
Abstract
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) exert potent vasculoprotective effects. However, the potential contribution to angiogenesis is controversial. In the present study, we demonstrate that atorvastatin dose-dependently affects endothelial cell migration and angiogenesis. In vivo relevant concentrations of 0.01 to 0.1 μmol/L atorvastatin or mevastatin promote the migration of mature endothelial cells and tube formation. Moreover, atorvastatin also increases migration and the potency to form vessel structures of circulating endothelial progenitor cells, which may contribute to vasculogenesis. In contrast, higher concentrations (>0.1 μmol/L atorvastatin) block angiogenesis and migration by inducing endothelial cell apoptosis. The dose-dependent promigratory and proangiogenic effects of atorvastatin on mature endothelial cells are correlated with the activation of the phosphatidylinositol 3-kinase–Akt pathway, as determined by the phosphorylation of Akt and endothelial NO synthase (eNOS) at Ser1177. In addition, the stimulation of migration and tube formation was blocked by phosphatidylinositol 3-kinase inhibitors. In contrast, the well-established stabilization of eNOS mRNA was achieved only at higher concentrations, suggesting that posttranscriptional activation rather than an increase in eNOS expression mediates the proangiogenic effect of atorvastatin. Taken together, these data suggest that statins exert a double-edged role in angiogenesis signaling by promoting the migration of mature endothelial cells and endothelial progenitor cells at low concentrations, whereas the antiangiogenic effects were achieved only at high concentrations.Keywords
This publication has 26 references indexed in Scilit:
- Inhibition of endothelial cell migration by cerivastatin, an HMG‐CoA reductase inhibitor: contribution to its anti‐angiogenic effectFEBS Letters, 2001
- Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adultsEuropean Journal of Clinical Pharmacology, 2001
- The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.Nature Medicine, 2000
- Phosphorylation of the endothelial nitric oxide synthase at Ser‐1177 is required for VEGF‐induced endothelial cell migrationFEBS Letters, 2000
- Current Perspectives on StatinsCirculation, 2000
- Regulation of endothelium-derived nitric oxide production by the protein kinase AktNature, 1999
- Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylationNature, 1999
- HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosisJournal of the American College of Cardiology, 1998
- Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPaseJournal of Biological Chemistry, 1998
- Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthaseProceedings of the National Academy of Sciences, 1998